<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="987">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780373</url>
  </required_header>
  <id_info>
    <org_study_id>prot. N. 71726</org_study_id>
    <nct_id>NCT04780373</nct_id>
  </id_info>
  <brief_title>Prognostic Score in Covid-19</brief_title>
  <official_title>Identification of a Clinical Score to Support the Clinician in Phase 2 of Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of L'Aquila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of L'Aquila</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to define the clinical and biochemical parameters that characterize&#xD;
      COVID-19 patients with a negative prognostic evolution. Our clinical score will be capable to&#xD;
      recognize patient with favorable prognosis or patient with poor prognosis by statistical data&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Data collection of clinical and demographical parameters of patients affected by COVID-19</measure>
    <time_frame>2 months</time_frame>
    <description>Data about sex, age, symptom start date, vital parameters, comorbidity, symptoms, hematochemicals blood tests, therapy, oxygen support, radiology, condition evaluation will be manual collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Application of statistical analysis on data of patients affected by COVID-19</measure>
    <time_frame>2 months</time_frame>
    <description>The collected data will be analyzed through descriptive statistics analysis, ROC curves, regression analysis, and Machine Learning techniques to predict the prognosis of patients affected by COVID-19.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Covid19 Prognostic Parameters</condition>
  <arm_group>
    <arm_group_label>Development cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>clinical data collection</description>
    <arm_group_label>Development cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Italian Caucasian Patients â‰¥ 18 years old SARS-CoV-2 infection confirmed by PCR&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients over 18 and symptomatic and positive for COVID-19 by polymerase chain&#xD;
             reaction assay for rhino-pharingeal swab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of L'Aquila</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of L'Aquila</investigator_affiliation>
    <investigator_full_name>Clara Balsano</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

